01 / ATLAS
What it is
DSIP stands for “delta sleep-inducing peptide” and is also known as emideltide. It has been investigated in sleep research. The name is not a guarantee that it induces sleep. [1]
02 / ATLAS
How it works
Research has examined effects on sleep structure and quality. The cited study does not provide a sufficient clinical explanation to predict who would benefit from administration. [1]
03 / ATLAS
What research shows
A double-blind study in people with chronic insomnia reported some differences in sleep efficiency and time to fall asleep. The authors considered the effects weak and potentially influenced by chance changes in the placebo group. [1]
04 / ATLAS
Study data
Bes et al., 1992: assessment using polysomnography and subjective ratings. The study is old, and the findings do not provide a sufficient basis for current clinical recommendations or self-medication doses. [1]
05 / ATLAS
Safety and observed adverse reactions
The FDA describes insufficient safety information for the proposed route and potential immunogenicity and impurity concerns. [2]
06 / ATLAS
Research status
The selected clinical evidence is limited. DSIP is not presented here as a validated insomnia treatment; persistent sleep disturbances require evaluation of their cause.
07 / REFERENCES
Studies and sources
- Bes et al. · DSIP in chronic insomnia (1992) ↗Original research · double-blind study
- FDA · Emideltide / DSIP ↗Official assessment · United States
